GlassScriptPhysician profile
Daniel S Kosches
NPI 1316932296
$5,030.81
in general payments reported to CMS, 2019-2025
20 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $434 · 2021: $489 · 2022: $816 · 2023: $462 · 2024: $558 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.26 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.25 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $476.95 | 2019 | |
| Braintree Laboratories, INC. | $437.33 | 2019-2025 | Suflave, Sutab |
| Janssen Biotech, INC. | $375.69 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $346.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $340.50 | 2022-2023 | Spravato |
| Allergan, INC. | $320.42 | 2019 | |
| Pfizer INC. | $274.70 | 2023-2025 | |
| Celgene Corporation | $263.08 | 2021-2023 | Zeposia |
| Otsuka America Pharmaceutical, INC. | $204.15 | 2019-2020 | |
| Redhill Biopharma INC. | $155.44 | 2021-2022 | |
| Lilly USA, LLC | $152.43 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $134.46 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $122.67 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $122.55 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $118.11 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $56.17 | 2020-2021 | |
| Romark Laboratories, Lc | $22.08 | 2019 | |
| Aimmune Therapeutics, INC. | $17.06 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kosches listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.